Overview
Dr Gary McCleane, MD, is a consultant in pain management with a particular interest in neuropathic pain, topical analgesics, novel options for pain management and he has a particular interest in Cholecystokinin antagonists. He has had over 70 papers published and has had 26 chapters on pain related topics included in a variety of text books. McCleane is the clinical leader on Merck’s L-365,260 and proglumide, which was marketed under the brand Milid.